These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 30560685)

  • 21. Pretreatment HIV drug resistance among adults initiating ART in Namibia.
    Taffa N; Roscoe C; Sawadogo S; De Klerk M; Baughman AL; Wolkon A; Mutenda N; DeVos J; Zheng DP; Wagar N; Prybylski D; Yang C; Hamunime N; Agolory S; Raizes E
    J Antimicrob Chemother; 2018 Nov; 73(11):3137-3142. PubMed ID: 30137412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV Drug Resistance Surveillance in Honduras after a Decade of Widespread Antiretroviral Therapy.
    Avila-Ríos S; García-Morales C; Tapia-Trejo D; Meza RI; Nuñez SM; Parham L; Flores NA; Valladares D; Pineda LM; Flores D; Motiño R; Umanzor V; Carbajal C; Murillo W; Lorenzana I; Palou EY; Reyes-Terán G
    PLoS One; 2015; 10(11):e0142604. PubMed ID: 26558396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States.
    Ross LL; Shortino D; Shaefer MS
    AIDS Res Hum Retroviruses; 2018 Aug; 34(8):672-679. PubMed ID: 29732898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone.
    Yendewa GA; Sahr F; Lakoh S; Ruiz M; Patiño L; Tabernilla A; Deen GF; Sesay M; Salata RA; Poveda E
    J Antimicrob Chemother; 2019 Jul; 74(7):2024-2029. PubMed ID: 30989237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 drug resistance genotyping from antiretroviral therapy (ART) naïve and first-line treatment failures in Djiboutian patients.
    Elmi Abar A; Jlizi A; Darar HY; Kacem MA; Slim A
    Diagn Pathol; 2012 Oct; 7():138. PubMed ID: 23044036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.
    Metzner KJ; Scherrer AU; von Wyl V; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Hirsch HH; Vernazza PL; Cavassini M; Calmy A; Bernasconi E; Weber R; Günthard HF;
    AIDS; 2014 Sep; 28(15):2231-9. PubMed ID: 25036184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.
    Moyo S; Gaseitsiwe S; Zahralban-Steele M; Maruapula D; Nkhisang T; Mokaleng B; Mohammed T; Ditlhako TR; Bareng OT; Mokgethi TP; van Widenfelt E; Pretorius-Holme M; Mine MO; Raizes E; Yankinda EK; Wirth KE; Gaolathe T; Makhema JM; Lockman S; Essex M; Novitsky V
    AIDS; 2019 May; 33(6):1073-1082. PubMed ID: 30946161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
    Simen BB; Simons JF; Hullsiek KH; Novak RM; Macarthur RD; Baxter JD; Huang C; Lubeski C; Turenchalk GS; Braverman MS; Desany B; Rothberg JM; Egholm M; Kozal MJ;
    J Infect Dis; 2009 Mar; 199(5):693-701. PubMed ID: 19210162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV Drug Resistance in Antiretroviral Treatment-Naïve Individuals in the Largest Public Hospital in Nicaragua, 2011-2015.
    Avila-Ríos S; García-Morales C; Matías-Florentino M; Tapia-Trejo D; Hernández-Álvarez BF; Moreira-López SE; Quant-Durán CJ; Porras-Cortés G; Reyes-Terán G
    PLoS One; 2016; 11(10):e0164156. PubMed ID: 27736898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.
    Meriki HD; Tufon KA; Anong DN; Atanga PN; Anyangwe IA; Cho-Ngwa F; Nkuo-Akenji T
    PLoS One; 2019; 14(11):e0225575. PubMed ID: 31751428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at term.
    Boyce CL; Beck IA; Styrchak SM; Hardy SR; Wallner JJ; Milne RS; Morrison RL; Shapiro DE; João EC; Mirochnick MH; Frenkel LM
    PLoS One; 2022; 17(9):e0275254. PubMed ID: 36166463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survey of Pretreatment HIV Drug Resistance and Genetic Transmission Network Analysis Among HIV Patients in a High Drug-Use Area of Southwest China.
    Liu L; Dong A; Liao L; Feng Y; Shao Y; Liang S; Ruan Y; Xing H
    Curr HIV Res; 2019; 17(6):441-451. PubMed ID: 31778107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
    Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
    Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.
    Musiime V; Kaudha E; Kayiwa J; Mirembe G; Odera M; Kizito H; Nankya I; Ssali F; Kityo C; Colebunders R; Mugyenyi P
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):449-55. PubMed ID: 23308370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005-2013.
    McCluskey SM; Lee GQ; Kamelian K; Kembabazi A; Musinguzi N; Bwana MB; Muzoora C; Haberer JE; Hunt PW; Martin JN; Boum Y; Bangsberg DR; Harrigan PR; Siedner MJ
    AIDS Patient Care STDS; 2018 Jul; 32(7):257-264. PubMed ID: 29985647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Virological failure and HIV-1 drug resistance mutations among naive and antiretroviral pre-treated patients entering the ESTHER program of Calmette Hospital in Cambodia.
    Barennes H; Guillet S; Limsreng S; Him S; Nouhin J; Hak C; Srun C; Viretto G; Ouk V; Delfraissy JF; Ségéral O
    PLoS One; 2014; 9(8):e105736. PubMed ID: 25166019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort.
    Telele NF; Kalu AW; Gebre-Selassie S; Fekade D; Marrone G; Grossmann S; Neogi U; Tegbaru B; Sönnerborg A
    BMC Infect Dis; 2019 Jul; 19(1):569. PubMed ID: 31262272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.